The effects of two mixed intravenous lipid emulsions on clinical outcomes in infants after gastrointestinal surgery: a prospective, randomized study
- 41 Downloads
There are many advantages of a SMOF emulsion (SMOF-lipid), such as liver-protective properties and anti-inflammatory effects. The objective of this study was to compare the clinical outcomes of SMOF-lipid with medium-chain triglycerides (MCT) /long-chain triglycerides (LCT) in infants after intestinal surgery.
This was a prospective, randomized study. Neonates receiving intravenous nutrient solution, including lipid emulsion after gastrointestinal surgery, were included in this study. The patients were randomly assigned to the SMOF-lipid or MCT/LCT groups. Infants who received intravenous lipid emulsion continuously for > 2 weeks were considered to have completed the study. Differences in weight gain, nutrition indices, alanine transaminase (ALT), aspartate transaminase (AST), and direct bilirubin (DB), and inflammation cytokine markers (interleukin [IL]-6 and tumor necrosis factor [TNF]-α) were measured.
The final sample included 160 infants. One hundred fourteen infants received intravenous SMOF-lipid (74) or MCT/LCT (86) > 2 weeks and 46 infants received intravenous SMOF-lipid (22) or MCT/LCT (24) > 4 weeks. There were no significant differences in weight gain, nutrition indices, inflammation cytokine markers, and sepsis between the groups at the end of 2 and 4 weeks; however, in the SMOF group, the ALT, AST, and DB levels were significantly lower than the MCT/LCT group at the end of 4 weeks.
The mixture and balanced emulsion of SMOF-lipid was well-tolerated in infants who have undergone gastrointestinal surgery, and liver-protective properties were demonstrated following long-term venous nutrition, especially > 4 weeks.
KeywordsLipid emulsions SMOF-lipid Medium-chain triglycerides (MCT)/long-chain triglycerides (LCT) Infants Gastrointestinal surgery Parenteral nutrition
This study was supported by the National Natural Science Foundation of China (81100318), the Jiangsu Provincial key research and development program (BE2017609), Jiangsu youth medical talent project (QNRC2016081), and Children’s Hospital of Nanjing Medical University youth medical talent project (ETYYQM2014009), Nanjing Science and Technology Project (201823015).
Compliance with ethical standards
Conflict of interest
The authors declare no conflict of interest.
- 20.Calkins KL, DeBarber A, Steiner RD et al. Intravenous fish oil and pediatric intestinal failure-associated liver sisease: changes in plasma phytosterols, cytokines, and bile acids and erythrocyte fatty acids. JPEN J Parenter Enteral Nutr. 2017. https://doi.org/10.1177/0148607117709196. (Epub ahead of print) CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Goulet O, Antebi H, Wolf C et al (2010) A new intravenous fat emulsion containing soybean oil, medium-chain triglycerides, olive oil, and fish oil: a single-center, double-blind randomized study on efficacy and safety in pediatric patients receiving home parenteral nutrition. J Parenter Enteral Nutr 34:485–495CrossRefGoogle Scholar
- 30.Angsten G, Finkel Y, Lucas S et al. Improved outcome in neonatal short bowel syndrome using parenteral fish oil in combination with ω-6/9 lipid emulsions. 2012;36:587–595Google Scholar